Literature DB >> 14576434

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Mary-Claire King1, Joan H Marks, Jessica B Mandell.   

Abstract

Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2. We selected 1008 index cases, regardless of family history of cancer, and carried out molecular analysis across entire families. The lifetime risk of breast cancer among female mutation carriers was 82%, similar to risks in families with many cases. Risks appear to be increasing with time: Breast cancer risk by age 50 among mutation carriers born before 1940 was 24%, but among those born after 1940 it was 67%. Lifetime risks of ovarian cancer were 54% for BRCA1 and 23% for BRCA2 mutation carriers. Physical exercise and lack of obesity in adolescence were associated with significantly delayed breast cancer onset.

Entities:  

Mesh:

Year:  2003        PMID: 14576434     DOI: 10.1126/science.1088759

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  706 in total

1.  [Computer experience and further developments in the respiratory function laboratory (author's transl)].

Authors:  R Schindl; K Mayer; K Aigner
Journal:  Med Klin       Date:  1975-11-07

Review 2.  Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.

Authors:  Alfons Meindl; Nina Ditsch; Karin Kast; Kerstin Rhiem; Rita K Schmutzler
Journal:  Dtsch Arztebl Int       Date:  2011-05-13       Impact factor: 5.594

3.  Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.

Authors:  Tom Walsh; Jessica B Mandell; Barbara M Norquist; Silvia Casadei; Suleyman Gulsuner; Ming K Lee; Mary-Claire King
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

Review 4.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

5.  High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Authors:  Banu Arun; Kristen J Vogel; Adriana Lopez; Mike Hernandez; Deann Atchley; Kristine R Broglio; Christopher I Amos; Funda Meric-Bernstam; Henry Kuerer; Gabriel N Hortobagyi; Constance T Albarracin
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

6.  BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study.

Authors:  Efrat Dagan; Yoram Cohen; Adi Mory; Vardit Adir; Zvi Borochowitz; Hila Raanani; Alina Kurolap; Svetlana Melikhan-Revzin; Dror Meirow; Ruth Gershoni-Baruch
Journal:  Eur J Hum Genet       Date:  2013-11-27       Impact factor: 4.246

Review 7.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

8.  Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary.

Authors:  Koah R Vierkoetter; Asia R Ayabe; Maya VanDrunen; Hyeong Jun Ahn; David M Shimizu; Keith Y Terada
Journal:  Gynecol Oncol       Date:  2014-08-02       Impact factor: 5.482

Review 9.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

10.  Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.

Authors:  Yuanyuan Fu; Nicoletta Biglia; Zhanwei Wang; Yi Shen; Harvey A Risch; Lingeng Lu; Emilie Marion Canuto; Wei Jia; Dionyssios Katsaros; Herbert Yu
Journal:  Gynecol Oncol       Date:  2016-09-23       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.